Chemotherapy for Primary Cardiac Sarcomas
Author Information
Author(s): A Liombart-Cussac, X Pivot, G Contesso, A Rhor-Alvarado, JP Delord, M Spielmann, T TOrsz, A Le Cesne
Primary Institution: Institut Gustave Roussy
Hypothesis
The study aims to evaluate the benefit of chemotherapy in patients with non-metastatic cardiac sarcomas after optimal resection.
Conclusion
Post-operative conventional doxorubicin-based chemotherapy failed to modify the natural history of patients with resected cardiac sarcomas.
Supporting Evidence
- 13 out of 15 patients relapsed after treatment.
- Median overall survival was 12 months.
- 2-year survival rate was 26%.
- Patients with completely resected tumors had longer survival than those with incomplete resections.
Takeaway
This study looked at patients with rare heart tumors and found that chemotherapy after surgery didn't help them live longer.
Methodology
The study analyzed 15 patients who underwent resection of primary cardiac sarcoma and received adjuvant chemotherapy.
Potential Biases
Potential selection bias due to the retrospective nature and exclusion of patients with unresectable tumors.
Limitations
The study is retrospective and has a small sample size.
Participant Demographics
Median age of participants was 45 years, with 11 males and 4 females.
Statistical Information
P-Value
P < 0.01
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website